( in Children Aged 6 to 12 Years With...)Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting,Health

in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder APA Poster# NR750 DAYTRANA (methylphenidate transdermal system): May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT) Efficacy and Safety of MTS in Male and Female Pediatric Subjects with ADHD APA Poster# NR665 May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT) 12-Month Efficacy and Tolerability of MTS in Children with ADHD APA Poster# NR664 ADDERALL XR (mixed salts of a single-entity amphetamine product): May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT) Long-Term Cardiovascular Safety of Mixed Amphetamine Salts Extended Release in Adolescents with ADHD APA Poster# NR652 SPD465 (triple-bead mixed amphetamine salts): May 21, 2007; 11:00 a.m. PDT (2:00 p.m. EDT) Extended Duration of Action of SPD465, a 16-Hour Mixed Amphetamine Salts Formulation, in the Treatment of Adults with ADHD Oral Presentation SPD503 (guanfacine HCl extended release): May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT) A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents with Attention- Deficit/Hyperactivity Disorder APA Poster# NR659 May 23, 2007; 12:00 p.m. PDT (3:00 p.m. EDT) Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder APA Poster# NR658

About VYVANSE and ADDERALL XR

VYVANSE or ADDERALL XR should not be taken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference